Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OPTimizing Adjuvant Prescription of PEMBROlizumab in Patients With Early-stage Triple-negative Breast Cancer Achieving Pathologic Complete Response After Standard Neoadjuvant Chemotherapy and Pembrolizumab

NCT06606730 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT06606730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06606730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OPTimizing Adjuvant Prescription of PEMBROlizumab in Patients With Early-stage Triple-negative Breast Cancer Achieving Pathologic Complete Response After Standard Neoadjuvant Chemotherapy and Pembrolizumab
Lead sponsor
UNICANCER
Phase
Phase 3
Overall status
Recruiting
Start date
July 23, 2025
Completion date
June 1, 2039
Enrollment
2,454 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancers, triple negative breast cancer (tnbc)